{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:27:50Z","timestamp":1790072870791,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T00:00:00Z","timestamp":1497571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/leu.2017.183","type":"journal-article","created":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T06:40:26Z","timestamp":1498027226000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis"],"prefix":"10.1038","volume":"32","author":[{"given":"G","family":"Martinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"De Benedittis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rondoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Papayannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Manfrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Meggendorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Calogero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Guadagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Bavaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Padella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Zago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Scaffidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Merante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Elena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Savini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Gangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Riccioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Morigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Delledonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Soverini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,16]]},"reference":[{"key":"BFleu2017183_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1056\/NEJMra1409760","volume":"373","author":"TC Theoharides","year":"2015","unstructured":"Theoharides TC, Valent P, Akin C . Mast cells, mastocytosis, and related disorders. N Engl J Med 2015; 373: 163\u2013172.","journal-title":"N Engl J Med"},{"key":"BFleu2017183_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603\u2013625.","journal-title":"Leuk Res"},{"key":"BFleu2017183_CR3","unstructured":"Horny HP, Akin C, Metcalfe DD, Escribano L, Bennett CB, Valent P et alMastocytosis (Mast cell disease). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (eds). World Health Organization (WHO) Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2008, pp 54\u201363."},{"key":"BFleu2017183_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391\u20132405.","journal-title":"Blood"},{"key":"BFleu2017183_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000236929","volume":"107","author":"Y Kitamura","year":"1995","unstructured":"Kitamura Y, Tsujimura T, Jippo T, Kasugai T, Kanakura Y . Regulation of development, survival and neoplastic growth of mast cells through the c-kit receptor. Int Arch Allergy Immunol 1995; 107: 54\u201356.","journal-title":"Int Arch Allergy Immunol"},{"key":"BFleu2017183_CR6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/leu.2015.24","volume":"29","author":"M Arock","year":"2015","unstructured":"Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia 2015; 29: 1223\u20131232.","journal-title":"Leukemia"},{"key":"BFleu2017183_CR7","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1084\/jem.20050807","volume":"202","author":"JP Zappulla","year":"2005","unstructured":"Zappulla JP, Dubreuil P, Desbois S, Letard S, Hamouda NB, Daeron M et al. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med 2005; 202: 1635\u20131641.","journal-title":"J Exp Med"},{"key":"BFleu2017183_CR8","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.4049\/jimmunol.180.8.5466","volume":"180","author":"M Mayerhofer","year":"2008","unstructured":"Mayerhofer M, Gleixner KV, Hoelbl A, Florian S, Hoermann G, Aichberger KJ et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol 2008; 180: 5466\u20135476.","journal-title":"J Immunol"},{"key":"BFleu2017183_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/leu.2009.37","volume":"23","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23: 900\u2013904.","journal-title":"Leukemia"},{"key":"BFleu2017183_CR10","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A . Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128\u20131138.","journal-title":"Leukemia"},{"key":"BFleu2017183_CR11","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","volume":"122","author":"J Schwaab","year":"2013","unstructured":"Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013; 122: 2460\u20132466.","journal-title":"Blood"},{"key":"BFleu2017183_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/leu.2015.4","volume":"29","author":"M Jawhar","year":"2015","unstructured":"Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny HP, Metzgeroth G et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia 2015; 29: 1115\u20131122.","journal-title":"Leukemia"},{"key":"BFleu2017183_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/leu.2015.284","volume":"30","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K et al. Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia 2016; 30: 136\u2013143.","journal-title":"Leukemia"},{"key":"BFleu2017183_CR14","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1038\/leu.2016.190","volume":"30","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Hausmann D, Clemens J, Naumann N, Henzler T et al. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia 2016; 30: 2342\u20132350.","journal-title":"Leukemia"},{"key":"BFleu2017183_CR15","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1002\/ajh.24273","volume":"91","author":"A Pardanani","year":"2016","unstructured":"Pardanani A, Lasho T, Barraco D, Patnaik M, Elala Y, Tefferi A . Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation. Am J Hematol 2016; 91: E10\u2013E11.","journal-title":"Am J Hematol"},{"key":"BFleu2017183_CR16","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/leu.2011.354","volume":"26","author":"MS Spector","year":"2012","unstructured":"Spector MS, Iossifov I, Kritharis A, He C, Kolitz JE, Lowe SW et al. Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor beta chain and KIT V654A. Leukemia 2012; 26: 1422\u20131425.","journal-title":"Leukemia"},{"key":"BFleu2017183_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1046\/j.1365-2567.2003.01559.x","volume":"108","author":"M Sundstrom","year":"2003","unstructured":"Sundstrom M, Vliagoftis H, Karlberg P, Butterfield JH, Nilsson K, Metcalfe DD et al. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology 2003; 108: 89\u201397.","journal-title":"Immunology"},{"key":"BFleu2017183_CR18","first-page":"S18","volume":"8","author":"Y Kanakura","year":"1994","unstructured":"Kanakura Y, Furitsu T, Tsujimura T, Butterfield JH, Ashman LK, Ikeda H et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 1994; 8: S18\u2013S22.","journal-title":"Leukemia"},{"key":"BFleu2017183_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440\u2013446.","journal-title":"Cancer Res"},{"key":"BFleu2017183_CR20","unstructured":"Team RC R: a language and environment for statistical computing. R Foundation for Satistical Computing: Vienna, Austria, 2016."},{"key":"BFleu2017183_CR21","first-page":"366","volume":"1846","author":"S Kudithipudi","year":"2014","unstructured":"Kudithipudi S, Jeltsch A . Role of somatic cancer mutations in human protein lysine methyltransferases. Biochim Biophys Acta 2014; 1846: 366\u2013379.","journal-title":"Biochim Biophys Acta"},{"key":"BFleu2017183_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cancergen.2014.10.005","volume":"208","author":"M Chopra","year":"2015","unstructured":"Chopra M, Bohlander SK . Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases. Cancer Genet 2015; 208: 192\u2013205.","journal-title":"Cancer Genet"},{"key":"BFleu2017183_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/sj.emboj.7601967","volume":"27","author":"JW Edmunds","year":"2008","unstructured":"Edmunds JW, Mahadevan LC, Clayton AL . Dynamic histone H3 methylation during gene induction: HYPB\/Setd2 mediates all H3K36 trimethylation. EMBO J 2008; 27: 406\u2013420.","journal-title":"EMBO J"},{"key":"BFleu2017183_CR24","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1128\/MCB.25.8.3305-3316.2005","volume":"25","author":"KO Kizer","year":"2005","unstructured":"Kizer KO, Phatnani HP, Shibata Y, Hall H, Greenleaf AL, Strahl BD . A novel domain in Set2 mediates RNA polymerase II interaction and couples histone H3 K36 methylation with transcript elongation. Mol Cell Biol 2005; 25: 3305\u20133316.","journal-title":"Mol Cell Biol"},{"key":"BFleu2017183_CR25","doi-asserted-by":"publisher","first-page":"18385","DOI":"10.1073\/pnas.0507975102","volume":"102","author":"B Li","year":"2005","unstructured":"Li B, Pattenden SG, Lee D, Gutierrez J, Chen J, Seidel C et al. Preferential occupancy of histone variant H2AZ at inactive promoters influences local histone modifications and chromatin remodeling. Proc Natl Acad Sci USA 2005; 102: 18385\u201318390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017183_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1074\/jbc.C500423200","volume":"281","author":"E Vojnic","year":"2006","unstructured":"Vojnic E, Simon B, Strahl BD, Sattler M, Cramer P . Structure and carboxyl-terminal domain (CTD) binding of the Set2 SRI domain that couples histone H3 Lys36 methylation to transcription. J Biol Chem 2006; 281: 13\u201315.","journal-title":"J Biol Chem"},{"key":"BFleu2017183_CR27","doi-asserted-by":"publisher","first-page":"15701","DOI":"10.1074\/jbc.M808431200","volume":"284","author":"W Yuan","year":"2009","unstructured":"Yuan W, Xie J, Long C, Erdjument-Bromage H, Ding X, Zheng Y et al. Heterogeneous nuclear ribonucleoprotein L Is a subunit of human KMT3a\/Set2 complex required for H3 Lys-36 trimethylation activity in vivo. J Biol Chem 2009; 284: 15701\u201315707.","journal-title":"J Biol Chem"},{"key":"BFleu2017183_CR28","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1038\/sj.onc.1210547","volume":"26","author":"LB Hesson","year":"2007","unstructured":"Hesson LB, Cooper WN, Latif F . Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 2007; 26: 7283\u20137301.","journal-title":"Oncogene"},{"key":"BFleu2017183_CR29","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477\u20132487.","journal-title":"N Engl J Med"},{"key":"BFleu2017183_CR30","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488\u20132498.","journal-title":"N Engl J Med"},{"key":"BFleu2017183_CR31","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/nm.3733","volume":"20","author":"M Xie","year":"2014","unstructured":"Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472\u20131478.","journal-title":"Nat Med"},{"key":"BFleu2017183_CR32","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","volume":"106","author":"J Gotlib","year":"2005","unstructured":"Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865\u20132870.","journal-title":"Blood"},{"key":"BFleu2017183_CR33","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"KV Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006; 107: 752\u2013759.","journal-title":"Blood"},{"key":"BFleu2017183_CR34","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","volume":"28","author":"SX Pfister","year":"2015","unstructured":"Pfister SX, Markkanen E, Jiang Y, Sarkar S, Woodcock M, Orlando G et al. Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Cancer Cell 2015; 28: 557\u2013568.","journal-title":"Cancer Cell"},{"key":"BFleu2017183_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature08672","volume":"463","author":"GL Dalgliesh","year":"2010","unstructured":"Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463: 360\u2013363.","journal-title":"Nature"},{"key":"BFleu2017183_CR36","doi-asserted-by":"crossref","first-page":"50719","DOI":"10.18632\/oncotarget.9368","volume":"7","author":"J Li","year":"2016","unstructured":"Li J, Duns G, Westers H, Sijmons R, van den Berg A, Kok K . SETD2: an epigenetic modifier with tumor suppressor functionality. Oncotarget 2016; 7: 50719\u201350734.","journal-title":"Oncotarget"},{"key":"BFleu2017183_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/ng.2894","volume":"46","author":"X Zhu","year":"2014","unstructured":"Zhu X, He F, Zeng H, Ling S, Chen A, Wang Y et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet 2014; 46: 287\u2013293.","journal-title":"Nat Genet"},{"key":"BFleu2017183_CR38","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1038\/ncomms4469","volume":"5","author":"BG Mar","year":"2014","unstructured":"Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 2014; 5: 3469.","journal-title":"Nat Commun"},{"key":"BFleu2017183_CR39","doi-asserted-by":"publisher","first-page":"e2004","DOI":"10.1097\/MD.0000000000002004","volume":"94","author":"W Liu","year":"2015","unstructured":"Liu W, Fu Q, An H, Chang Y, Zhang W, Zhu Y et al. Decreased expression of SETD2 predicts unfavorable prognosis in patients with nonmetastatic clear-cell renal cell carcinoma. Medicine (Baltimore) 2015; 94: e2004.","journal-title":"Medicine (Baltimore)"},{"key":"BFleu2017183_CR40","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.juro.2016.06.010","volume":"196","author":"J Wang","year":"2016","unstructured":"Wang J, Liu L, Qu Y, Xi W, Xia Y, Bai Q et al. Prognostic value of SETD2 expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. J Urol 2016; 196: 1363\u20131370.","journal-title":"J Urol"},{"key":"BFleu2017183_CR41","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1038\/leu.2016.134","volume":"30","author":"H Parker","year":"2016","unstructured":"Parker H, Rose-Zerilli MJ, Larrayoz M, Clifford R, Edelmann J, Blakemore S et al. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. Leukemia 2016; 30: 2179\u20132186.","journal-title":"Leukemia"},{"key":"BFleu2017183_CR42","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1038\/onc.2015.24","volume":"34","author":"N Kanu","year":"2015","unstructured":"Kanu N, Gronroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J et al. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene 2015; 34: 5699\u20135708.","journal-title":"Oncogene"},{"key":"BFleu2017183_CR43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1182\/asheducation-2015.1.98","volume":"2015","author":"P Valent","year":"2015","unstructured":"Valent P . Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. Hematology Am Soc Hematol Educ Program 2015; 2015: 98\u2013105.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFleu2017183_CR44","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","volume":"32","author":"C Ustun","year":"2014","unstructured":"Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014; 32: 3264\u20133274.","journal-title":"J Clin Oncol"},{"key":"BFleu2017183_CR45","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","volume":"126","author":"S Barete","year":"2015","unstructured":"Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris MO, Elie C et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood 2015; 126: 1009\u20131016, quiz 1050.","journal-title":"Blood"},{"key":"BFleu2017183_CR46","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1182\/blood-2008-08-175190","volume":"114","author":"KJ Aichberger","year":"2009","unstructured":"Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, Ferenc V et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 2009; 114: 5342\u20135351.","journal-title":"Blood"},{"key":"BFleu2017183_CR47","doi-asserted-by":"publisher","first-page":"e02482","DOI":"10.7554\/eLife.02482","volume":"3","author":"S Carvalho","year":"2014","unstructured":"Carvalho S, Vitor AC, Sridhara SC, Martins FB, Raposo AC, Desterro JM et al. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. Elife 2014; 3: e02482.","journal-title":"Elife"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017183","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:08:00Z","timestamp":1684433280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,16]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFleu2017183"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.183","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,16]]},"assertion":[{"value":"6 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}